Pharmaceutical

Gilead acquires CymaBay Therapeutics for $4.3bn

Gilead Sciences has concluded the acquisition of CymaBay Therapeutics in a transaction valued at approximately $4.3bn.

Mar 26, 2024 - 00:00
Gilead acquires CymaBay Therapeutics for $4.3bn
Gilead Sciences has concluded the acquisition of CymaBay Therapeutics in a transaction valued at approximately $4.3bn.
Read the original article

Tags:

Previous Article

Birmingham University to develop lollipop for mouth cancer detection

Next Article

FDA approves J&J’s OPSYNVI for pulmonary arterial hypertension

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA AdCom to question efficacy and safety concerns with Eli Lilly’s Alzheimer’s drug

FDA AdCom to question efficacy and safety concerns with...

Jun 8, 2024

UK Government expands opioid overdose treatment access

UK Government expands opioid overdose treatment access

May 15, 2024

ITM raises $273 million to fund radionuclide therapy pipeline

ITM raises $273 million to fund radionuclide therapy pi...

Jun 5, 2023